

Special Issue

Advanced Single-Cell Sequencing in Diseases

Message from the Guest Editor

For this Special Issue, “Advanced Single-Cell Sequencing in Diseases”, we welcome studies that apply single-cell and spatial transcriptomic analyses to explore the cellular diversity and molecular mechanisms underlying various diseases. We invite submissions that use either newly generated or publicly available single-cell datasets to perform analyses such as clustering, annotation, and visualization with UMAP, DotPlot, FeaturePlot, or comparable approaches. Studies utilizing Seurat, Scanpy, or related bioinformatics frameworks for data processing, integration, and interpretation are highly encouraged. Papers comparing disease and control conditions, identifying cell-type-specific gene expression changes, or characterizing novel cellular subpopulations across tissues and models are particularly welcome. The scope includes all disease areas and experimental systems that employ single-cell data to draw biological conclusions. Our aim is to compile a collection of data-driven analyses demonstrating how single-cell technologies and computational tools can advance our understanding of disease biology. We look forward to receiving your contributions.

Guest Editor

Dr. Sedat Kacar
Pulmonary Division, Indiana University School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions

31 July 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/261025

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).